SCHEMBL2992355

SCHEMBL2992355

CN(C)CCNC(=O)c1ccc(N)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.49
HIF1A Q16665 1/20 0.48
ALOX15 P16050 1/20 0.48
POLB P06746 1/20 0.47
MAPK1 P28482 2/20 0.47
CHEK2 O96017 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.44
SLC22A2 O15244 1/20 0.44
SLC22A1 O15245 1/20 0.44
TSHR P16473 1/20 0.44
ACHE P22303 1/20 0.44
CYP2C19 P33261 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
MALT1 Q9UDY8 1/20 0.44
CYP1A2 P05177 1/20 0.44
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993766 0.93 ALOX15 (0.56) MAOBHIF1AALOX15POLBALDH1A1
SCHEMBL1674346 0.86 ALDH1A1 (0.63) MAOBHIF1APOLBMAPK1ALDH1A1
SCHEMBL30074614 0.82 ALOX15 (0.48) MAOBALOX15POLBMAPK1ALDH1A1
SCHEMBL21531023 0.82 ALOX15 (0.48) MAOBALOX15POLBMAPK1ALDH1A1
SCHEMBL30074608 0.82 ALOX15 (0.48) MAOBALOX15POLBMAPK1ALDH1A1
SCHEMBL23293634 0.82 ALOX15 (0.48) MAOBALOX15POLBMAPK1ALDH1A1
SCHEMBL30074571 0.82 ALOX15 (0.48) MAOBALOX15POLBMAPK1ALDH1A1
SCHEMBL21531034 0.82 CYP1A2 (0.57) MAOBALOX15POLBMAPK1ALDH1A1
SCHEMBL30074581 0.82 ALOX15 (0.48) MAOBALOX15POLBMAPK1ALDH1A1
SCHEMBL3000781 0.82 MAOB (0.51) MAOBHIF1AMALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US claimed
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US claimed
US-12194109-B2 Radioactive compound for treatment of melanoma and use thereof INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) 2025-01-14 US disclosed
EP-3816156-A1 RADIOACTIVE COMPOUND FOR TREATMENT OF MELANOMA AND USE THEREOF Industry Foundation of Chonnam National University (KR) 2021-05-05 EP disclosed
US-20210113719-A1 RADIOACTIVE COMPOUND FOR TREATMENT OF MELANOMA AND USE THEREOF INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) 2021-04-22 US disclosed
US-20210113719-A1 RADIOACTIVE COMPOUND FOR TREATMENT OF MELANOMA AND USE THEREOF INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) 2021-04-22 US disclosed
CN-112601740-A Radioactive compounds for the treatment of melanoma and uses thereof 全南大学校产学协力团 2021-04-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12194109-B2 Radioactive compound for treatment of melanoma and use thereof CD47, TYR, NRAS MAOB 1807/4885HIF1A 371/4885ALOX15 3201/4885
US-20210113719-A1 RADIOACTIVE COMPOUND FOR TREATMENT OF MELANOMA AND USE THEREOF CD47, TYR, NRAS MAOB 1807/4885HIF1A 371/4885ALOX15 3201/4885
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 MAOB 3222/4885HIF1A 2401/4885ALOX15 3350/4885
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 MAOB 3222/4885HIF1A 2401/4885ALOX15 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.